Ateroks

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ateroks

Property Description
Active ingredient Atorvastatin calcium trihydrate
Form Tablet (oral)
Pharmacological class Statins (HMG-CoA reductase inhibitor)
General purpose Lipid profile improvement / Cardiovascular risk reduction
Origin Synthetic compound

Ateroks is a prescription-only medicine containing the synthetic compound Atorvastatin, and is classified primarily as a lipid-lowering medicine. It belongs to the pharmacological class of statins, formally identified as HMG-CoA reductase inhibitors. Statins are a class of prescription drugs used with diet and exercise to reduce blood levels of low-density lipoprotein (LDL) cholesterol. This distinction lies in being one of the most clinically recognized moderate-to-high-intensity statins, used for modulating blood lipid levels.

Atorvastatin: The Core Active Ingredient

The core active compound in Ateroks is Atorvastatin, supplied as the calcium salt, specifically Atorvastatin calcium trihydrate. The medication is prepared for ingestion as a tablet for oral administration, along with essential pharmaceutical excipients. This formulation ensures the compound is delivered internally to the liver, which is the body's primary site of cholesterol production. Atorvastatin works by slowing the production of cholesterol in the body. The efficacy of the synthetic structure is well-established, allowing the compound to consistently achieve its targeted therapeutic goal.

General Purpose: Lipid Profile Management

The general purpose of Ateroks is to facilitate lipid profile improvement by managing key circulating blood fats, particularly low-density lipoprotein cholesterol (LDL-C). By directly inhibiting the cholesterol production process, Atorvastatin enables the medicine to lower concentrations of circulating LDL-C.

This action is crucial for contributing to the essential goal of reducing the long-term risk associated with cholesterol accumulation in the arteries. This is central to the established cardiovascular health strategies that utilize statin therapy, confirming its role in comprehensive lipid modification for adult patients.

What side effects are possible with Ateroks?

Adverse reaction scope

Component Description
Key adverse reaction categories Side effects categorized by frequency and by System-Organ Class (e.g., Musculoskeletal, Gastrointestinal, Nervous System). Includes serious events like myopathy and hepatic failure.
Frequency classification Common (ge 1/100 to <1/10): Nasopharyngitis, pain in extremity, arthralgia, headache, nausea, diarrhea, dyspepsia, flatulence, myalgia, and liver enzyme elevations. Rare (ge 1/10,000 to <1/1,000): Myopathy, rhabdomyolysis, and hepatitis.
System-organ classes involved Infections and Infestations, Musculoskeletal and Connective Tissue Disorders, Gastrointestinal Disorders, Hepatobiliary Disorders, and Nervous System Disorders.
Serious adverse reactions (as documented in regulatory sources) Myopathy (including Immune-Mediated Necrotizing Myopathy), Rhabdomyolysis (severe muscle breakdown), and Hepatic Failure (fatal and non-fatal). An increased incidence of Hemorrhagic Stroke has been observed at the highest dose in patients with a recent stroke or TIA.
Population-specific safety considerations (if applicable) Hepatic Impairment: Contraindicated in patients with active liver disease. Pregnancy and Lactation: Contraindicated due to the potential for fetal harm. Older Adults (ge 65 years): Considered to have a higher risk for some adverse reactions.
Dose- or exposure-related patterns (if explicitly stated) The risk of myopathy and rhabdomyolysis is documented as dose-related. Rare reports of cognitive impairment (memory loss, confusion) are generally reversible upon discontinuation of treatment.
Safety-related restrictions or limitations Contraindicated in active liver disease, unexplained persistent elevated liver enzymes, and during pregnancy or breastfeeding. The risk of myopathy is increased when used with certain interacting medications.

Safety classifications (high-level)

  • Regulatory frequency framework used (e.g., EMA / ICH frequency bands): Adverse reactions are classified using standardized frequency categories (Common, Rare) based on incidence rates from clinical trials and post-marketing reports, reflecting how regulatory bodies communicate risk.
  • Regulatory basis (EMA / FDA / other government authority): The safety profile is established and monitored by authoritative regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
  • Context-of-use safety notes (as defined in official documents): The use of statins is associated with increases in HbA1 c and fasting serum glucose levels. Monitoring of liver function tests is a mandated regulatory requirement due to the potential for enzyme elevations.

Resulting safety structure

  • The official safety profile systematically separates frequently reported general side effects from rare, clinically serious adverse events via formal frequency classification.
  • It identifies specific organ system risks, focusing on Musculoskeletal and Hepatobiliary disorders, which require defined regulatory precautions.
  • Explicit contraindications are established for active liver disease and pregnancy, and the risk of myopathy is contextualized as dose-related and influenced by concomitant medication use.

Connection to the overall safety profile: The regulatory safety profile comprehensively structures the understanding of potential risks by defining the frequency and system location of adverse reactions, ensuring clear differentiation between common occurrences and serious events. This rigorous documentation, mandated by government health authorities, provides explicit limitations for use, such as contraindications for active liver disease and pregnancy, thereby framing the medicine's risk profile in a neutral, evidence-based manner.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory labeling does not define a unique set of clinical manifestations specifically characteristic of acute Atorvastatin overdose. The primary concern and management guidance focuses instead on the potential for severe, high-exposure-related organ toxicity.

The most serious outcomes documented in the regulatory profile include rhabdomyolysis, a severe breakdown of muscle tissue, and subsequent acute kidney injury or renal failure. High exposure is associated with the requirement to monitor key laboratory markers such as Creatine Kinase (CK) levels and liver function tests to track the extent of potential organ injury.

There is no specific treatment or antidote known for Atorvastatin overdosage, according to the official prescribing information. For this reason, management is restricted to the institution of symptomatic and supportive measures as medically necessary. Regulatory constraints note that due to the drug’s extensive plasma protein binding, clearance is not expected to be significantly enhanced by haemodialysis.

Urgent medical attention is required in the event of any suspected overdose or if severe symptoms occur. Immediate contact with emergency services is mandated if an individual exhibits signs such as collapse, seizure, difficulty breathing, or inability to be awakened.

Therapeutic Uses of Ateroks

Ateroks is generally applied for two key therapeutic areas: the long-term management of abnormal blood fat levels and managing the risk for serious cardiovascular events. It is classified as a moderate-to-high-intensity statin, commonly relevant when diet and lifestyle measures alone may be insufficient to achieve therapeutic goals.


Managing Unhealthy Lipid Profiles and Risk Contexts

Ateroks is relevant in conditions characterized by systemic imbalance, specifically to address asymptomatic metabolic abnormalities found in blood tests, primarily high Low-Density Lipoprotein Cholesterol (LDL-C) and elevated Triglycerides. It is commonly applied across conditions presenting with systemic discomfort and functional stress related to cardiovascular health, including Primary Hypercholesterolemia, Mixed Dyslipidemia, and Familial Hypercholesterolemia. Ateroks contributes to reducing the amount of harmful cholesterol in the bloodstream, which supports the management of plaque formation (atherosclerosis) in the arteries.

“The therapy is generally applied for chronic management, supporting the patient's stability against potential long-term consequences of high cholesterol.”

The medication is commonly relevant in the clinical context of Primary Prevention in high-risk adults (e.g., those with Type 2 Diabetes Mellitus) and for Secondary Prevention in patients with established disease (e.g., following a heart attack or stroke). Continuous use may assist in addressing the potential for symptoms linked to vascular impairment, such as serious cardiovascular events, thereby assisting with maintaining functional stability over the long term.


QuickFact: Management of Vascular Impairment Risk

Ateroks supports general well-being by contributing to the reduction of the overall risk load related to future major vascular events, which may help patients maintain a more stable health profile over time.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Population Eligibility and Regulatory Restrictions for Ateroks (Atorvastatin)

Eligibility for Ateroks is determined strictly by regulatory authorities, focusing on a patient's medical history, age, and reproductive status. The medicine is contraindicated and must not be used in several defined populations.

Absolute Non-Eligibility (Contraindications)

Ateroks is prohibited for individuals with active liver disease, including unexplained, persistent elevations of serum liver enzymes (transaminases). It is also strictly contraindicated for anyone with a known hypersensitivity to the active compound, Atorvastatin, or any excipients.

Contraindicated Status Specific Population Group
Reproductive Status Women who are pregnant, breastfeeding, or of child-bearing potential not using effective contraception.
Hepatic Status Patients with active liver disease or decompensated cirrhosis.

Conditional Use and Age Restrictions

Use in children under 10 years of age is generally not established for most indications, though it is approved for adolescents (10–17 years) with specific forms of familial high cholesterol. Caution is required for patients with predisposing factors for myopathy, such as uncontrolled hypothyroidism, renal impairment, or advanced age (ge 65 years). Use in these populations requires careful monitoring, as detailed in the regulatory labeling.

What should I know about interactions with other medicines?

Ateroks (atorvastatin) can interact with a wide range of other medicines, potentially increasing the risk of serious side effects, such as muscle problems (myopathy or rhabdomyolysis) or changes in the levels of Ateroks or the other drug in the body. It is essential to inform your healthcare provider about all prescription and non-prescription medicines, vitamins, and herbal supplements you are currently taking.

Increased Risk of Muscle Problems

The risk of muscle-related side effects is significantly higher when Ateroks is combined with certain drugs. Close medical monitoring, a change in dosage, or an alternative therapy may be required with:

  • Fibrates: (e.g., gemfibrozil, fenofibrate)
  • Immunosuppressants: (e.g., ciclosporin)
  • Antifungals: (e.g., itraconazole, ketoconazole)
  • Certain Antibiotics: (e.g., erythromycin, clarithromycin, fusidic acid)
  • HIV/Hepatitis C Medicines: (e.g., ritonavir, telaprevir)
  • Colchicine: Used for gout

Other Notable Interactions

Type of Interaction Examples of Medicines/Products
Dosage adjustment may be needed Verapamil, diltiazem (for heart conditions), Digoxin, Oral contraceptives, Warfarin
May reduce Ateroks effectiveness Rifampin, St. John's Wort
Avoid or limit consumption Large quantities of Grapefruit Juice (more than 1.2 liters per day), Alcohol

It is crucial to follow your doctor's specific advice regarding potential interactions and dosage adjustments.

Mechanism of Action

Ateroks (Atorvastatin) operates through a two-fold mechanism that primarily influences hepatic lipid homeostasis and secondarily modulates vascular cell function. The drug’s core action involves the competitive inhibition of a specific enzyme and the resulting biological cascades.

Rate-Limiting Inhibition of Cholesterol Synthesis

The drug acts as a competitive inhibitor of the enzyme HMG-CoA reductase in the liver. This enzyme is the critical speed controller of the Mevalonate pathway, which is responsible for the body’s internal cholesterol manufacturing. By blocking this rate-limiting step, the drug inhibits the synthesis of new cholesterol, establishing a state of deficit within the hepatic cells.

Enhanced LDL Receptor Clearance

The state of reduced internal cholesterol synthesis triggers a compensatory feedback mechanism: the liver cells respond by significantly increasing the number of Low-Density Lipoprotein (LDL) receptors on their surface. This enhanced receptor density increases the liver's capacity to actively bind and remove circulating LDL-C particles from the bloodstream, resulting in the reduction of circulating atherogenic lipids.

Vascular Functional Modulation (Pleiotropic Effects)

Beyond lipid lowering, the pathway interference restricts the production of key molecular intermediates called isoprenoids. This reduction functionally modulates signaling proteins within the vessel wall (e.g., Rho/Rac), which influences the endothelial lining and local inflammatory processes. These mechanisms contribute to a change in vascular cell function independent of the immediate reduction in circulating cholesterol.

Dosage and Administration Information

Ateroks, which contains the active compound Atorvastatin, is intended for oral administration as a film-coated tablet. The medicine is taken once daily and is established as a chronic therapy. For consistency, the tablet is typically taken at approximately the same time each day, although administration is permitted with or without food and at any time of the day. The tablets must be swallowed whole to ensure proper use. Ateroks therapy is initiated as an adjunct to a cholesterol-lowering diet.

Official Dosing Regimens

The standard adult dosage regimen spans a range of 10 mg to 80 mg once daily. Treatment typically begins with a starting dose of 10 mg or 20 mg. For patients requiring a large reduction in low-density lipoprotein cholesterol (LDL-C), a starting dose of 40 mg once daily may be used. The maximum approved dose in adults is 80 mg once daily. Following initiation, the dose is assessed, and adjustments are made at intervals of 4 weeks or more. If a dose is missed, the standard procedure is to skip the missed dose and continue with the next scheduled dose, as doubling the dose is not recommended.

Population-Specific Use

Regarding population-specific instructions, no dose adjustment is routinely required for older adults or individuals with renal impairment. For pediatric patients aged 10 to 17 years, the maximum recommended dose for heterozygous familial hypercholesterolemia is 20 mg once daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ateroks

Evidence for use in Chronic Pain

Ateroks was studied for use related to the condition of chronic pain. Researchers primarily used short-term Randomized Controlled Trials (RCTs) to assess outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. These trials included adults who had chronic pain lasting ge 3 months. Studies reported measurements of changes in patient-reported pain severity scores over the initial 4 to 12 weeks of the trials. Evidence contributes to understanding symptom patterns in these specific research settings, but these findings describe group patterns, not personal outcomes.

Evidence for use in Acute Inflammation

Ateroks was evaluated in studies focused on conditions involving periods of heightened symptoms linked to inflammatory or irritative states. The research primarily consisted of short-term trials. Studies explored how Ateroks was associated with outcomes describing episodic or acute changes and physiological strain. Research highlights changes measured during the study period in biomarkers related to systemic or functional imbalance. This research provides context but does not determine whether an individual will respond similarly.

Evidence for use in Anxiety Disorder

Research examined Ateroks in the context of conditions associated with acute or disruptive episodes and those marked by functional limitations related to anxiety. Studies monitored patient-reported outcomes describing perceived discomfort and functional measures. Research describes patterns observed related to outcomes reflecting daily functioning or activity level in the study populations. The results apply only to the populations studied.

Long-term Studies and Follow-up

Long-term effects are not fully established by controlled, blinded research. For Ateroks, most controlled research involves short-to-intermediate timeframes. Longer-duration data is observed in open-label extensions or observational settings evaluating daily-life functioning. This extended research describes usage patterns and monitors outcomes in observational settings over several years, but certainty remains low regarding sustained changes.

What is still uncertain about Ateroks

Limited information for long-term outcomes is a key gap. Findings were mixed across studies examining specific patient-reported outcomes, suggesting that evidence quality varies across studies due to differences in design and populations. Data for certain groups, such as those under the age of 18 or those with specific co-occurring medical conditions, remain insufficient for a complete picture.

Frequently Asked Questions (FAQ)

Common questions about Ateroks (FAQ)


Q: Is Ateroks safe to take long-term?

A: Ateroks is described in regulatory documents as a chronic therapy, meaning it is intended for long-term use. While clinical trials often focus on intermediate timeframes, extended safety data is gathered from observational studies. Regulatory reviews ensure continued monitoring of potential rare adverse events, particularly those related to muscle and liver function, throughout its use.


Q: Are there any common vitamins or supplements that might interact with Ateroks?

A: Official product information notes specific supplements that may interact with the drug. The herbal supplement St. John's Wort is explicitly listed as potentially reducing the effectiveness of Ateroks. Additionally, taking high doses of Niacin (Vitamin B3) has been associated with an increased risk of muscle-related issues.


Q: Can Ateroks cause stomach upset, and if so, how is it managed?

A: Gastrointestinal issues, such as nausea, diarrhea, and indigestion (dyspepsia), are common side effects listed in official documents. Authoritative patient information sources describe simple approaches, such as consuming bland meals and maintaining adequate hydration, that may help manage these symptoms.


Q: Is Ateroks an anti-inflammatory drug?

A: Ateroks is formally classified as a lipid-lowering medicine that works by inhibiting cholesterol production. While regulatory documents state the drug class is associated with effects that modulate local inflammatory processes, its main purpose and classification remain focused on blood fat management, not on treating inflammation directly.


Q: Does Ateroks affect fertility in men or women?

A: The drug is contraindicated for women who are pregnant or of child-bearing potential not using effective contraception, due to regulatory concern regarding potential fetal harm. Official regulatory documents do not specify a reduction in the ability to conceive in men or women during use.


Q: Is Ateroks a blood thinner?

A: No, Ateroks is not an anticoagulant (blood thinner). The drug is classified as an HMG-CoA reductase inhibitor, commonly known as a statin. Its primary function is to reduce the body’s internal production of cholesterol and increase the removal of fats from the bloodstream.


Q: How quickly can someone expect Ateroks to start working?

A: Ateroks is rapidly absorbed, with the highest concentration of the drug in the blood typically occurring within one to two hours of taking it. The maximum therapeutic effect on cholesterol lowering is typically reached after approximately four weeks of consistent use.


Q: What is the biggest difference between Ateroks and other drugs used for similar conditions?

A: Ateroks belongs to the class of HMG-CoA reductase inhibitors, or statins. This mechanism is distinct because it targets the body's internal cholesterol manufacturing pathway in the liver. Other drugs for similar conditions may work differently, such as by binding cholesterol in the gut or increasing the liver’s ability to clear fats from the blood.


Q: Why is Ateroks sometimes described as a 'prophylactic' medicine?

A: The term 'prophylactic' refers to a measure taken to prevent disease. According to official documents, Ateroks is indicated for the prevention of cardiovascular events, such as a heart attack or stroke, in adults who are already at an increased risk. This intended preventive use is why it may be described this way.


Q: Can Ateroks affect my sleep?

A: Regulatory safety reviews have noted that sleep disturbances have been reported as adverse effects associated with the statin class of medicines. These disturbances can include reports of insomnia (difficulty sleeping) or experiencing nightmares.


Q: Can people with high blood pressure take Ateroks?

A: Yes. High blood pressure (hypertension) is not listed as a contraindication for Ateroks. In fact, Ateroks is indicated for use in patients who are at increased risk for cardiovascular disease, a group that often includes those managing high blood pressure.


Q: Does Ateroks have a risk of addiction?

A: Official adverse event reporting for Ateroks, mandated by government authorities, does not contain any references regarding dependence or addiction potential.


Q: Is there a generic version of Ateroks available?

A: Ateroks is a brand name. The active compound, Atorvastatin, is the generic name for this medicine. Generic versions containing the active compound Atorvastatin are approved by government regulatory bodies.


Q: Why is the drug Ateroks sometimes prescribed in combination with other medicines?

A: Regulatory documentation specifically allows Ateroks to be used as part of 'concomitant lipid-lowering therapy.' This is because some patients require the combined effect of Ateroks and another type of cholesterol-lowering medicine to meet their specific therapeutic goals for fat reduction.


Q: Is it true that Ateroks can cause dizziness in some people?

A: Health information from authoritative bodies notes that some individuals taking medicines in the statin class, including Ateroks, may experience dizziness or a feeling of weakness. This symptom has been noted in post-marketing reports for the drug class.


Q: Is Ateroks considered a high-risk medication?

A: Ateroks is a widely used prescription medication subject to regulatory oversight. Official labeling includes Warnings and Precautions related to potential serious, but rare, events such as muscle damage (rhabdomyolysis) and liver failure.


Q: Can I drink coffee while taking Ateroks?

A: Official drug interaction information primarily lists interactions with specific medicines, Grapefruit Juice, and Alcohol. There is no official statement or warning in the regulatory labeling regarding the consumption of coffee or caffeine.


Q: What is the typical age range of people who are prescribed Ateroks?

A: Ateroks is approved for use across a wide age range. It is approved for use in adolescents aged 10 to 17 years for certain forms of high cholesterol, and for adults of all ages, including older adults.


Q: Does Ateroks interact with over-the-counter pain relievers like ibuprofen?

A: The official labeling does not list a specific direct interaction between Ateroks and nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, caution is advised with certain concomitant medications, as they can increase the risk of gastrointestinal issues.


Q: Why is consistent use of Ateroks important?

A: Ateroks is designated for chronic, long-term therapy. The benefits in reducing cardiovascular risk are strongly linked to the sustained, consistent presence of the drug in the body, which supports its designation for chronic therapy.


Q: Are skin rashes a possible side effect of Ateroks?

A: Yes, official adverse reaction reports and safety updates have documented various skin reactions. These can include generalized skin rash and urticaria (hives), which range from common to rare in occurrence.


Q: How long after stopping Ateroks does the drug stay in my system?

A: The mean elimination half-life of the parent drug is approximately 14 hours. However, the overall cholesterol-lowering activity, which is maintained by active components and metabolites, is officially noted to last longer, typically ranging from 20 to 30 hours.


Q: Can Ateroks affect the results of other medical tests?

A: Yes. Regulatory documentation specifically notes that Ateroks use may be associated with increased levels of HbA1 c (a measure of average blood sugar) and fasting serum glucose. Monitoring of liver function test results is also a mandatory requirement.


Q: Is Ateroks a cure for the condition it treats?

A: No, Ateroks is not described as a cure in official regulatory documents. It is indicated for the management of high blood fats and is intended to be used as an adjunct to diet and lifestyle changes to reduce long-term cardiovascular risk.


Q: Do official documents mention any effects of Ateroks on mood or anxiety?

A: While not primary side effects, official safety updates have reviewed reports regarding cognitive impairment (such as confusion or memory loss) and depression associated with the statin class. A specific, listed adverse effect on anxiety is not noted in regulatory documents.


Q: Is Ateroks used globally, or only in certain countries?

A: Ateroks, or its generic equivalent Atorvastatin, is approved and regulated by major governmental health authorities worldwide, including the U.S. FDA and the European EMA. This indicates the drug is in extensive global use.


Q: Is Ateroks mentioned in major medical guidelines for its condition?

A: Yes. The active ingredient in Ateroks, Atorvastatin, is a recognized component of global lipid management strategies. It is explicitly categorized by major medical guidelines (such as those from cardiology associations) as a high-intensity or moderate-intensity statin.


Q: Can I take Ateroks if I have a history of ulcers?

A: A history of ulcers or gastrointestinal bleeding is not listed as a contraindication for Ateroks use. However, patients should be aware that common side effects include gastrointestinal upset, and certain concomitant medications, which can impact ulcer risk, may require caution.

How should Ateroks be stored and disposed of?

How to Store and Dispose of Ateroks

Official regulatory documents specify the exact conditions required for storing Ateroks (atorvastatin) tablets to maintain product stability.

Storage Environment

Ateroks must be stored at a controlled room temperature, which is generally defined as below 30 C or between 20 C and 25 C (68 F and 77 F). To prevent degradation, the product must be kept in the original package and the container must remain tightly closed to protect the tablets from light and moisture, away from excess heat.

Disposal and Safety

All medicines, including Ateroks, must be stored out of the sight and reach of children. Unused or expired tablets should be disposed of via an authorized drug take-back program. If a program is unavailable, official guidance recommends mixing the medicine with an undesirable substance and discarding it in a sealed container in the household trash, while explicitly advising against flushing it down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ateroks found in:

A-Z Index: